Analysts Expect Transcat, Inc. (NASDAQ:TRNS) Will Announce Quarterly Sales of $46.04 Million


Share on StockTwits

Equities analysts expect Transcat, Inc. (NASDAQ:TRNS) to report sales of $46.04 million for the current quarter, Zacks Investment Research reports. Three analysts have made estimates for Transcat’s earnings. The lowest sales estimate is $45.15 million and the highest is $46.60 million. Transcat posted sales of $45.76 million during the same quarter last year, which suggests a positive year-over-year growth rate of 0.6%. The firm is expected to report its next quarterly earnings results on Tuesday, May 18th.

According to Zacks, analysts expect that Transcat will report full year sales of $170.62 million for the current year, with estimates ranging from $169.72 million to $171.20 million. For the next financial year, analysts forecast that the company will post sales of $183.53 million, with estimates ranging from $179.61 million to $185.90 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research analysts that cover Transcat.

Transcat (NASDAQ:TRNS) last announced its quarterly earnings results on Wednesday, February 3rd. The scientific and technical instruments company reported $0.23 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.19 by $0.04. Transcat had a net margin of 4.01% and a return on equity of 10.08%. The company had revenue of $44.06 million for the quarter, compared to analyst estimates of $43.34 million.

Several brokerages have recently commented on TRNS. Colliers Securities restated a “buy” rating and set a $43.50 price target on shares of Transcat in a research note on Monday, March 8th. HC Wainwright raised their target price on shares of Transcat from $42.00 to $48.00 and gave the company a “buy” rating in a research note on Thursday, February 4th. Sidoti lowered shares of Transcat from a “buy” rating to a “neutral” rating and set a $54.00 target price on the stock. in a research note on Monday, March 29th. Roth Capital raised their target price on shares of Transcat from $35.00 to $45.00 and gave the company a “buy” rating in a research note on Thursday, February 4th. Finally, Craig Hallum raised their target price on shares of Transcat from $36.00 to $49.00 and gave the company a “buy” rating in a research note on Thursday, February 4th. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Transcat has a consensus rating of “Buy” and a consensus price target of $47.79.

Shares of TRNS traded down $0.93 during mid-day trading on Friday, hitting $48.98. 22,766 shares of the company’s stock were exchanged, compared to its average volume of 45,812. The firm has a fifty day moving average of $48.87 and a two-hundred day moving average of $37.66. Transcat has a twelve month low of $22.87 and a twelve month high of $54.15. The stock has a market cap of $364.71 million, a price-to-earnings ratio of 53.82, a P/E/G ratio of 5.00 and a beta of 0.70. The company has a quick ratio of 1.54, a current ratio of 2.20 and a debt-to-equity ratio of 0.30.

In other Transcat news, CEO Lee D. Rudow sold 1,000 shares of the stock in a transaction on Wednesday, January 20th. The shares were sold at an average price of $36.50, for a total value of $36,500.00. Following the completion of the sale, the chief executive officer now directly owns 162,187 shares of the company’s stock, valued at approximately $5,919,825.50. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Over the last three months, insiders sold 8,230 shares of company stock valued at $417,147. Insiders own 7.90% of the company’s stock.

A number of institutional investors have recently modified their holdings of TRNS. Marshall Wace North America L.P. lifted its holdings in shares of Transcat by 157.5% during the 1st quarter. Marshall Wace North America L.P. now owns 1,545 shares of the scientific and technical instruments company’s stock worth $36,000 after acquiring an additional 945 shares during the period. California Public Employees Retirement System lifted its holdings in shares of Transcat by 5.0% during the 3rd quarter. California Public Employees Retirement System now owns 14,800 shares of the scientific and technical instruments company’s stock worth $434,000 after acquiring an additional 700 shares during the period. Squarepoint Ops LLC bought a new position in shares of Transcat during the 3rd quarter worth about $256,000. Conestoga Capital Advisors LLC lifted its holdings in shares of Transcat by 7.5% during the 4th quarter. Conestoga Capital Advisors LLC now owns 50,250 shares of the scientific and technical instruments company’s stock worth $1,743,000 after acquiring an additional 3,500 shares during the period. Finally, Leverage Partners Absolute Return Fund SPC bought a new position in shares of Transcat during the 4th quarter worth about $520,000. 70.57% of the stock is owned by hedge funds and other institutional investors.

Transcat Company Profile

Transcat, Inc provides calibration and laboratory instrument services in North America and internationally. It operates in two segments, Service and Distribution. The Service segment offers calibration, repair, inspection, analytical qualification, preventative maintenance, consulting, and other related services.

Featured Article: What are economic reports?

Get a free copy of the Zacks research report on Transcat (TRNS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Transcat (NASDAQ:TRNS)

Receive News & Ratings for Transcat Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Transcat and related companies with MarketBeat.com's FREE daily email newsletter.